The GeneXpert diagnostic testing technology from the US-based corporation Cepheid has revolutionised rapid, accurate diagnosis of tuberculosis (TB) since entering the market in 2010. Yet, due to the high cost of the GeneXpert instrument and its tests, most high TB-burden countries are not able to scale up testing for all people who need diagnosis.
